The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorChinese PLA General Hospital

About this trial

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients age between 18 and 80 year old, both sex

papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration

the largest diameter ≤2.0 cm

no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT

Disqualifiers

patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy

history of neck radiation

history of thyroid surgery

coagulation disorder

Trial population

patients with low-risk papillary thyroid carcinoma who choose surgery or thermal ablation

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • thyroid surgery

    Procedure/Surgery

    thyroid lobectomy

  • ultrasound-guided thermal ablation

    Procedure/Surgery

    radiofrequency ablation; microwave ablation or laser ablation

Treatment groups

3,772 Participants
are divided into 2 treatment groups
Group A: surgery group1 intervention
Group B: ablation group1 intervention

Trial outcomes

Primary outcomes

1

rate of disease progression

cervical lymph node metastases, recurrent tumors and persistent tumors

Time frame
more than 5 year

Secondary outcomes

1

Rate of complications

surgery or ablation complications

Time frame
1week
2

Rate of tumor disappearance

complete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound

Time frame
2 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.